Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
2(17%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
6
50%
Ph phase_1
2
17%
Ph phase_4
2
17%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
6(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 42 (20.0%)
N/A6 (60.0%)

Trials by Status

terminated18%
completed975%
active_not_recruiting217%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
PROCEDURE
Total Trials
12